Weimin Mao

机构：Guangxi University, Guangxi Medical University, Wenzhou Medical University, Riverside University Health System - Medical Center, First Affiliated Hospital of Jiangxi Medical College, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, First Affiliated Hospital of GuangXi Medical University, Hangzhou Cancer Hospital

发表论文 173 篇 · 总被引 6318 次 · h-index 32

代表论文

• Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial (2023 · Signal Transduction and Targeted Therapy · 被引 84)
• Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer (2022 · Journal of Clinical Oncology · 被引 66)
• Lymph Node Ratio Improves Prediction of Overall Survival in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy: A National Cancer Database Analysis (2022 · Annals of Surgery · 被引 40)
• Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma (2022 · Translational Lung Cancer Research · 被引 29)
• Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010 (2022 · Journal of Thoracic and Cardiovascular Surgery · 被引 28)
• Novel Marker for Predicting Prognosis in Hepatitis B Virus-Associated Decompensated Cirrhosis: Monocyte-To-Albumin Ratio (2023 · Clinical Laboratory · 被引 13)